Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Sekisui Diagnostics

For 40 years SEKISUI Diagnostics has been committed to providing innovative medical diagnostics to physicians and lab... read more Featured Products: More products

Download Mobile App




Urinary Biomarkers Predict Weaning From Acute Dialysis Therapy

By LabMedica International staff writers
Posted on 29 Nov 2022

Acute kidney injury is associated with a higher risk of chronic kidney disease (CKD), end-stage renal disease, and long-term adverse cardiovascular effects. Critically ill patients with acute kidney injury (AKI) requiring renal replacement therapy (RRT) have a poor prognosis.

Several urinary biomarkers that can predict the development of AKI have been identified, including proximal renal tubular damage markers (e.g., liver-type fatty acid–binding protein [L-FABP], hemojuvelin [HJV], and kidney injury molecule 1 [KIM-1]), distal renal tubular damage markers (e.g., neutrophil gelatinase-associated lipocalin [NGAL] ), and inflammation markers (e.g., C-C motif chemokine ligand 14 [CCL14] and interleukin 18 [IL-18].

Nephrologists at the National Taiwan University Hospital (Taipei, Taiwan) and their colleagues prospectively recorded and analyzed clinical variables at several time points: (1) before starting renal replacement therapy (RRT), (2) at the time of weaning off RRT, and (3) 24 hours after stopping RRT. A total of 140 critically ill patients who received RRT at a multicenter referral hospital from August 2016 to January 2019 were enrolled.

At the time of stopping RRT, urine samples were collected and stored at −80 °C until analysis. The urine concentrations of novel AKI biomarkers were determined using enzyme-linked immunosorbent assay kits: renal L-FABP, (Sekisui Medical Co, Ltd, Tokyo, Japan); KIM-1, NGAL, CCL14 and IL-18, (R&D Systems, Minneapolis, MN, USA), HJV, (Cloud-Clone Corp, Katy, TX, USA).

The investigators reported that the 90-day mortality rate was 13.6% (19/140), and 47.9% (67/140) of the patients were successfully weaned from RRT. Cluster analysis showed that the following biomarkers were correlated with estimated glomerular filtration rate at the time of weaning off RRT: urinary neutrophil gelatinase-associated lipocalin, kidney injury molecule 1, hemojuvelin, C-C motif chemokine ligand 14, interleukin 18, and liver-type fatty acid–binding protein (L-FABP). Among these, urinary L-FABP/creatinine (uL-FABP/Cr) at the time of weaning off RRT showed the best predictive performance for mortality (area under the receiver operating characteristic curve = 0.79).

The authors concluded that nearly half of the critically ill AKI-RRT patients in this study were successfully weaned from acute RRT. They demonstrated that uL-FABP/Cr level at the time of weaning from RRT independently predicted being dialysis free for more than 90 days and all-cause mortality. They also showed that a cutoff value of uL-FABP/Cr (log) level ≤ 2.2 μg/g Cr may be useful for clinical decision-making for AKI-RRT patients who attempt to wean off RRT. uL-FABP/Cr can be combined with SOFA score at the time of weaning off RRT to predict being dialysis free and 90-day mortality. The study was published in the November, 2022 issue of the journal Archives of Pathology & Laboratory Medicine.


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Liquid Ready-To-Use Lp(a) Reagent
Lipoprotein (a) Reagent
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.